Medscape commentary calls 'easy way out' GLP-1 stigma a clinical problem

A commentary published September 4, 2026, by Medscape argues that the common belief that GLP-1 medications are an "easy way out" is not just a social attitude but a clinical problem — one that can keep patients from telling their doctors they use the drugs and push some toward unsupervised sources ^[1].

The piece is by Yoni Freedhoff, MD, an associate professor in the department of family medicine at the University of Ottawa. It responds to a recently published opinion piece in Nature's International Journal of Obesity that called for conceptual clarity around GLP-1s and treatment-related stigma ^[1]. Freedhoff writes that the stigma rests on the belief that weight loss belongs to "effort, hard work, and discipline," not medication, and that people with obesity are often assumed to lack those qualities. People who lose weight with the drugs, he writes, are then stereotyped as having skipped the work. The result, in his phrasing, is a "damned if they do and damned if they don't" situation: blamed for taking the easy way out when they use medication, and blamed if they cannot keep weight off without it ^[1].

Both writers agree the framing has consequences. Freedhoff notes that weight stigma is already linked to harms to mental health and physical health, eating disorders and stress. Stigma tied to GLP-1 use, he argues, can reasonably be expected to produce similar outcomes — and also to reduce how long people stay on the drugs, to become a barrier to care if patients avoid appointments rather than face shame for considering medication, and to steer people toward "questionable and less evidence-based resources" ^[1]. The commentary's own key points list lower adherence, less care-seeking and more avoidance of physician visits as expected effects ^[1].

Where the two authors part ways is the trend line. Freedhoff writes that the Nature author expects quick-fix stigma to grow, in a landscape where 25% of Americans have already at least tried a GLP-1 and 100 million people would be eligible for a prescription ^[1]. Freedhoff expects the opposite: that as comfort with the medications and understanding of how they work spread through society and the medical profession, obesity will come to be described as a chronic noncommunicable disease, like hypertension, for which taking medication does not draw blame. He estimates that shift will take "the better part of a decade or two" ^[1]. He also raises the possibility that a new stigma will replace the old one — scorn for people who choose not to take the drugs or cannot ^[1].

The Medscape article is commentary and review, not new data. Its list of unanswered questions includes what predicts GLP-1 discontinuation due to stigma, how stigma affects adherence outcomes, and which interventions reduce obesity-related medication stigma ^[1]. The author disclosure for Freedhoff lists a clinical grant from Novo Nordisk to Constant Health, equity interests in Bariatric Medical Institute and Constant Health, and income from Random House ^[1].

Why it matters for patients

For anyone taking or considering a GLP-1, the argument is about what happens outside the prescription. If patients hide their use from clinicians or skip appointments to avoid judgment, they lose the monitoring and dose management that come with supervised care. If they stop treatment early because of how it looks to others, they lose whatever benefit the drug was providing. And if they look for alternatives they can obtain without a conversation, the article warns they may end up with products and programs that have less evidence behind them ^[1].

The commentary also matters because it separates two things that are often lumped together: judgment about body weight and judgment about how weight was lost. Freedhoff treats medication-related stigma as its own problem, with its own possible effects on whether people start, continue or disclose treatment ^[1]. What has not been reported is how often stigma actually causes someone to stop a GLP-1, or which specific approaches reduce it — both appear on the article's list of open questions ^[1].

What happens next

No studies, guidelines or policy changes are announced in the commentary, and no dates are attached to the open questions it lists ^[1]. The only timeline offered is Freedhoff's own estimate that the shift in how obesity and its medications are viewed will take "the better part of a decade or two" ^[1]. Medscape also publishes a clinician-facing answer on obesity stigma, which says clinicians increasingly emphasize person-first language, nonjudgmental counseling and recognition of obesity as a chronic disease to reduce shame and improve care-seeking and follow-up ^[1].